QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)

Gilead Sciences (GILD) Stock Price, News & Analysis

-0.60 (-0.82%)
(As of 02/26/2024 ET)
Today's Range
50-Day Range
52-Week Range
5.18 million shs
Average Volume
7.79 million shs
Market Capitalization
$90.90 billion
P/E Ratio
Dividend Yield
Price Target

Gilead Sciences MarketRank™ Stock Analysis

Analyst Rating
2.27 Rating Score
17.7% Upside
$85.86 Price Target
Short Interest
1.26% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.18mentions of Gilead Sciences in the last 14 days
Based on 33 Articles This Week
Insider Trading
Selling Shares
$1.13 M Sold Last Quarter
Proj. Earnings Growth
From $7.07 to $7.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.99 out of 5 stars

Medical Sector

5th out of 942 stocks

Biological Products, Except Diagnostic Industry

2nd out of 152 stocks

GILD stock logo

About Gilead Sciences Stock (NASDAQ:GILD)

Gilead Sciences, Inc. is a leading biopharmaceutical company in Foster City, California. Founded in 1987, the company's mission is to develop innovative medicines that address unmet medical needs and improve the lives of people around the world. Gilead focuses on discovering, developing, and commercializing therapies in HIV/AIDS, liver diseases, oncology, inflammatory and respiratory diseases, and cardiovascular conditions. 

Gilead's portfolio includes a wide range of products and therapies, with its most notable product being Truvada, a leading medication for HIV prevention. The company also offers other HIV treatments, such as Biktarvy and Descovy. In addition to its HIV franchise, Gilead has significantly advanced in treating chronic hepatitis B and C with drugs like Veklury and Epclusa. Furthermore, the company has expanded into oncology with therapies such as Trodelvy and Yescarta.

Gilead Sciences is led by experienced executives who bring industry knowledge and expertise. The company's Chief Executive Officer, Daniel O'Day, joined Gilead in 2019 and has a proven track record in the pharmaceutical industry. O'Day previously served as the CEO of Roche Pharmaceuticals, where he successfully led the company through significant growth.

Gilead Sciences has consistently delivered a solid financial performance in recent years. The company has reported strong revenue and net income numbers yearly. This growth was primarily driven by solid sales of Gilead's HIV and liver disease therapies. The company averages a profit margin between 25% - 30%. Gilead has maintained a healthy balance sheet with manageable levels of debt. Gilead's strong financial position allows it to invest in research and development initiatives and pursue strategic acquisitions to drive future growth.

Investor sentiment towards Gilead has improved in recent years due to the company's strong financial performance and promising pipeline of innovative therapies. The successful launch of new products, such as Trodelvy and Biktarvy, has further bolstered investor confidence in Gilead's growth prospects.

Gilead Sciences operates in the highly competitive biopharmaceutical industry, characterized by rapid innovation, high research and development costs, and stringent regulatory requirements. The industry is subject to evolving market dynamics, including changing reimbursement policies, patent expirations, and intense competition from established and emerging biotech firms.

Gilead's expansion into oncology has been promising, with the introduction of therapies targeting specific types of cancer. However, the oncology market is highly competitive, with several significant players and emerging biotechs vying for market share. Gilead's success in this area will depend on its ability to differentiate its products, demonstrate clinical efficacy, and navigate the evolving treatment landscape.

Gilead Sciences has identified several growth opportunities that can contribute to its future success. One key focus is expanding its product portfolio through internal research and development efforts and strategic acquisitions and partnerships. By investing in innovative therapies, Gilead aims to address unmet medical needs and strengthen its competitive position.

The company's pipeline includes potential breakthrough treatments for various diseases, including novel antiviral agents, immunology candidates, and cell therapies. Gilead also explores combination therapies to enhance treatment outcomes and extend its market reach. These advancements provide opportunities for revenue growth and market expansion.

Gilead Sciences faces risks and challenges that could impact its performance and prospects. One of the primary challenges for Gilead is the potential for generic competition. As patents on some of its key products expire, there is a risk of generic manufacturers entering the market with lower-priced alternatives. This can lead to pricing pressures and a decline in market share for Gilead's established therapies. The company must continue to innovate and develop new drugs to mitigate the impact of generic competition.

Another challenge is the evolving regulatory environment. Changes in healthcare policies, pricing regulations, and reimbursement systems can significantly impact the profitability of pharmaceutical companies. Gilead operates in multiple regions and must navigate various regulatory frameworks, which can introduce uncertainties and challenges to its business operations.

Additionally, Gilead faces intense competition from established pharmaceutical and smaller biotech firms. Rapid technological advancements and evolving treatment paradigms characterize the industry. Competitors may develop new therapies or gain regulatory approvals threatening Gilead's market share. The company must continue to invest in research and development to maintain its competitive edge.

Clinical trial failures and delays are also inherent risks in the biopharmaceutical industry. Despite rigorous research and development processes, there is always a possibility that promising drug candidates may fail to meet efficacy or safety requirements during clinical trials. These setbacks can result in significant financial losses and delays in product launches, impacting Gilead's revenue streams.

Additionally, Gilead faces the challenge of addressing changing treatment landscapes and shifting patient preferences. Medical advancements, scientific discoveries, and evolving disease patterns can alter the demand for specific therapies. Gilead must anticipate and adapt to these changes to ensure its products remain relevant and effective.

Risk management is crucial for Gilead Sciences to mitigate potential challenges. The company employs rigorous clinical trial protocols, invests in diverse therapeutic areas, and pursues strategic partnerships to diversify its product portfolio. Gilead's strong financial position allows it to navigate uncertainties and invest in research and development initiatives. Furthermore, the company monitors regulatory developments and engages with policymakers to shape favorable healthcare policies.

GILD Stock Price History

GILD Stock News Headlines

Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.
Gene therapy: Why does it cost millions for a single treatment? (GILD)
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Analysts see over 50% gains in these 2 mid-cap biotech stocks (GILD)
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Mizuho Trims Gilead Sciences (NASDAQ:GILD) Target Price to $90.00
Gilead Sciences (NASDAQ:GILD) Lowered to Hold at Truist Financial
GILD Feb 2024 110.000 call
See More Headlines
Receive GILD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/28 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 3/28 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
15 Analysts


Net Income
$5.67 billion
Pretax Margin


Sales & Book Value

Annual Sales
$27.12 billion
Cash Flow
$6.38 per share
Book Value
$18.26 per share


Outstanding Shares
Free Float
Market Cap
$90.96 billion

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Daniel P. O'Day (Age 60)
    Chairman & CEO
    Comp: $7.27M
  • Mr. Andrew D. DickinsonMr. Andrew D. Dickinson (Age 54)
    Executive VP & CFO
    Comp: $2.94M
  • Ms. Deborah H. Telman (Age 59)
    Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
    Comp: $2.32M
  • Ms. Johanna  MercierMs. Johanna Mercier (Age 53)
    Chief Commercial Officer
    Comp: $3.32M
  • Dr. Merdad V. Parsey M.D. (Age 60)
    Ph.D., Chief Medical Officer
    Comp: $3.07M
  • Ms. Sandra Patterson (Age 57)
    Senior VP, Corporate Controller & Principal Accounting Officer
  • Ms. Jacquie Ross C.F.A.
    Vice President of Investor Relations
  • Ms. Jyoti K. Mehra (Age 48)
    Executive Vice President of Human Resources
  • Dr. Linda Slanec Higgins Ph.D. (Age 62)
    Senior Vice President of Research, Innovation & Portfolio
  • Dr. Rudolf Ertl (Age 78)
    Senior Vice President of Commercial Operations of Australia, Canada, Europe

Should I Buy Gilead Sciences Stock? GILD Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Wednesday, February 21, 2024 at 2:09 PM.

GILD Stock Analysis - Frequently Asked Questions

Should I buy or sell Gilead Sciences stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 1 sell rating, 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings
or view top-rated stocks.

What is Gilead Sciences' stock price target for 2024?

15 Wall Street research analysts have issued twelve-month price targets for Gilead Sciences' stock. Their GILD share price targets range from $71.00 to $105.00. On average, they predict the company's stock price to reach $85.86 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price.
View analysts price targets for GILD
or view top-rated stocks among Wall Street analysts.

How have GILD shares performed in 2024?

Gilead Sciences' stock was trading at $81.01 at the beginning of the year. Since then, GILD stock has decreased by 9.9% and is now trading at $72.95.
View the best growth stocks for 2024 here

Are investors shorting Gilead Sciences?

Gilead Sciences saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 15,660,000 shares, a drop of 8.6% from the January 15th total of 17,140,000 shares. Based on an average trading volume of 7,200,000 shares, the days-to-cover ratio is presently 2.2 days. Currently, 1.3% of the company's shares are short sold.
View Gilead Sciences' Short Interest

When is Gilead Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our GILD earnings forecast

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Tuesday, February, 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts' consensus estimates of $1.76 by $0.04. The biopharmaceutical company earned $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a trailing twelve-month return on equity of 38.85%. The firm's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period last year, the business posted $1.67 earnings per share.
Read the conference call transcript

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences declared a quarterly dividend on Thursday, February 1st. Investors of record on Friday, March 15th will be given a dividend of $0.77 per share on Thursday, March 28th. This represents a $3.08 dividend on an annualized basis and a yield of 4.22%. The ex-dividend date is Thursday, March 14th. This is a boost from the stock's previous quarterly dividend of $0.75.
Read our dividend analysis for GILD

Is Gilead Sciences a good dividend stock?

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $3.00 per share and currently has a dividend yield of 4.08%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 66.67%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GILD will have a dividend payout ratio of 40.00% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY 2024 earnings guidance on Tuesday, February, 6th. The company provided EPS guidance of 6.850-7.250 for the period, compared to the consensus earnings per share estimate of 7.210. The company issued revenue guidance of $27.1 billion-$27.5 billion, compared to the consensus revenue estimate of $27.7 billion.

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.97%), Capital World Investors (6.69%), Capital Research Global Investors (4.79%), Dodge & Cox (2.67%), Norges Bank (1.29%) and Northern Trust Corp (1.13%). Insiders that own company stock include Andrew D Dickinson, Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Johanna Mercier, Merdad Parsey and Richard James Whitley.
View institutional ownership trends

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Gilead Sciences have any subsidiaries?
The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Forty Seven Holdings LLC, Forty Seven Inc., Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (GSR) S.R.L., Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Colombia S.A.S., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences Ilac Ticaret Limited Sirketi, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland Unlimited Company, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, Immunomedics Inc., KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, MYR, MYR GmbH, MYR Pharmaceuticals France SAS, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..
Read More
This page (NASDAQ:GILD) was last updated on 2/26/2024 by MarketBeat.com Staff